Arrow
Arrow
Slider

Premaitha Health PLC
(“Premaitha”, the “Company” or the “Group”)

Half year results

Manchester, UK – 29 December 2017: Premaitha Health PLC (AIM: NIPT), a leading molecular diagnostics group with a primary focus on the commercialisation of its non-invasive prenatal testing (“NIPT”) technology, announces half year results for the six months ended 30 September 2017.

Financial highlights
•    Revenues increased by 87% to £2.7m (H1 2016/17: £1.5m)
•    Test volumes doubled to over 22,000 (H1 2016/17: 11,000)
•    Gross profit up 120% to £1.3m, 48% of revenues (H1 2016/17: £0.6m, 41%)
•    Operating loss increased to £4.7m (H1 2016/17:  £3.5m) due to £1.3m charge to increase litigation provision
•    Recovery efforts continuing for debts owed by Swiss customer, Genoma SA (“Genoma”), including successful application to place Genoma in bankruptcy in May 2017
•    Further $5.0m investment by Thermo Fisher in July 2017 in form of loan facility extension and associated warrants
•    Cash and cash equivalents at 30 September 2017 of £1.6m (not including R&D tax credits of £0.6m) (30 September 2016: £2.7m)
•    Continued focus on achieving positive pre-litigation cashflows by year-end March 2018
•    Litigation funding scenarios under review in light of adverse judgment in November 2017 and potential developments in Q1 2018

Operational highlights
•    Integration of Yourgene Bioscience (“Yourgene”) acquisition completed successfully and synergies already being realised
•    Significant commercial progress:
    o Expansion of customer base and increased market penetration in existing territories including: India; South East Asia; Middle East and Europe
    o Entry into new markets with customers secured in East Asia and South Africa
    o IONA® test approved for Brazilian Good Manufacturing Practice
• Product development roadmap delivering enhancements and range expansion:
    o IONA® test validated on Thermo Fisher’s Ion S5 range of instruments
    o Launched Sage™ remote analysis prenatal screening solution
• Patent litigation continues to create significant headwinds:
    o Further UK patent infringement claim filed by Illumina in September 2017, counter-application by Premaitha for abuse of legal process to be heard in March 2018
    o Post period-end received adverse UK first instance judgment in relation to ongoing dispute with Illumina, appeal in preparation
    o Active engagement continues with EU Competition Commission for anti-trust defence

Dr Stephen Little, CEO of Premaitha, said: “We continue to make excellent commercial progress, with revenues up 87% and test volumes doubling. In the last 6 months, the Group has made significant strides in expanding the business and de-risking its intellectual property position through international expansion. Today, less than 20% of the Group’s revenues are impacted by the UK judgment.  Recent laboratory installations and public policy implementations will drive further growth in 2018 and will further reduce the percentage of our revenues from the UK as our share of the very substantial global NIPT market continues to grow – a market which is forecast to exceed $1 billion by 2021.

“We were very disappointed by the first instance judgment in the UK in relation to the Illumina NIPT patent claims, for which we are preparing a robust appeal ahead of the next hearing in late January 2018.  The potential scenarios remain complex and we are reviewing how best to achieve a de-risked IP landscape for investors and customers, with appropriate working capital in place to realise the significant global potential for the Group in 2018 and beyond.

“The Group remains focused on product development and international expansion. We have built a very strong network of distributors and customers in the NIPT space from which we expect to see substantial growth as awareness of the benefits of NIPT continues to grow. In addition, we are accelerating efforts to leverage Premaitha’s scientific expertise into other applications of our molecular diagnostics technology and look forward to announcing exciting developments in due course.”
 
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For more information, please contact:   
 
Premaitha Health PLC
Dr Stephen Little, Chief Executive Officer
Barry Hextall, Chief Financial Officer
Joanne Cross, Head of Marketing
This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: +44 (0)161 667 105
 
Cairn Financial Advisers LLP (NOMAD)
Liam Murray / James Caithie   
Tel: +44 (0)20 7213 0880

finnCap (Broker)
Adrian Hargrave / Scott Mathieson (Corporate Finance)
Andrew Burdis / Abigail Wayne (Corporate Broking)   
Tel: +44 (0)20 7220 0500

Vigo Communications
Ben Simons / Fiona Henson / Antonia Pollock
This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: +44 (0)20 7830 9700
 
About Premaitha

Premaitha is an international molecular diagnostics group which uses the latest advances in DNA analysis technology to develop safer, faster and regulatory approved genetic screening tests. The Group’s primary focus is on non-invasive prenatal tests (NIPT) for pregnant women – an emerging, multi-billion dollar global market.

Premaitha’s IONA® test was launched in 2015 as the first CE-IVD NIPT test in Europe. It enables laboratories and healthcare practitioners to offer a complete CE-marked NIPT system in-house. The IONA® test is performed on a maternal blood sample – which contains traces of fetal DNA – and estimates the risk of a fetus being affected with Down’s syndrome or other genetic conditions.

Unlike existing prenatal screening methods, due to its high level of accuracy, the IONA® test can significantly reduce the number of women subjected to unnecessary invasive follow up diagnostic procedures, such as amniocentesis, which are costly, resource intensive and carry a risk of miscarriage.

In March 2017, Premaitha acquired Yourgene Bioscience, a specialist next generation sequencing and bioinformatics company based in Taiwan, with its own NIPT screening test that operates on the same Thermo Fisher next-generation sequencing platform as Premaitha’s IONA® test. Yourgene brings significant benefits to the Group through expanded market access in Asia – the world’s fastest growing NIPT market – as well as opportunities for cross-selling and the ability to jointly develop expanded test content both within NIPT and beyond.

Premaitha is headquartered in Manchester, England, with Yourgene offices in Taipei and Singapore. Its shares trade on the AIM market of the London Stock Exchange (AIM: NIPT). For further information, please visit www.premaitha.com. Follow us on twitter @PremaithaHealth.

Premaitha Health PLC

(“Premaitha”, the “Company” or the “Group”)

Half year results

Manchester, UK – 29 December 2017: Premaitha Health PLC (AIM: NIPT), a leading molecular diagnostics group with a primary focus on the commercialisation of its non-invasive prenatal testing (“NIPT”) technology, announces half year results for the six months ended 30 September 2017.

Financial highlights

·       Revenues increased by 87% to £2.7m (H1 2016/17: £1.5m)

·       Test volumes doubled to over 22,000 (H1 2016/17: 11,000)

·       Gross profit up 120% to £1.3m, 48% of revenues (H1 2016/17: £0.6m, 41%)

·       Operating loss increased to £4.7m (H1 2016/17: £3.5m) due to £1.3m charge to increase litigation provision

·       Recovery efforts continuing for debts owed by Swiss customer, Genoma SA (“Genoma”), including successful application to place Genoma in bankruptcy in May 2017

·       Further $5.0m investment by Thermo Fisher in July 2017 in form of loan facility extension and associated warrants

·       Cash and cash equivalents at 30 September 2017 of £1.6m (not including R&D tax credits of £0.6m) (30 September 2016: £2.7m)

·       Continued focus on achieving positive pre-litigation cashflows by year-end March 2018

·       Litigation funding scenarios under review in light of adverse judgment in November 2017 and potential developments in Q1 2018

Operational highlights

·       Integration of Yourgene Bioscience (“Yourgene”) acquisition completed successfully and synergies already being realised

·       Significant commercial progress:

o   Expansion of customer base and increased market penetration in existing territories including: India; South East Asia; Middle East and Europe

o   Entry into new markets with customers secured in East Asia and South Africa

o   IONA® test approved for Brazilian Good Manufacturing Practice

·       Product development roadmap delivering enhancements and range expansion:

o   IONA® test validated on Thermo Fisher’s Ion S5 range of instruments

o   Launched Sage™ remote analysis prenatal screening solution

·       Patent litigation continues to create significant headwinds:

o   Further UK patent infringement claim filed by Illumina in September 2017, counter-application by Premaitha for abuse of legal process to be heard in March 2018

o   Post period-end received adverse UK first instance judgment in relation to ongoing dispute with Illumina, appeal in preparation

o   Active engagement continues with EU Competition Commission for anti-trust defence

Dr Stephen Little, CEO of Premaitha, said: “We continue to make excellent commercial progress, with revenues up 87% and test volumes doubling. In the last 6 months, the Group has made significant strides in expanding the business and de-risking its intellectual property position through international expansion. Today, less than 20% of the Group’s revenues are impacted by the UK judgment.  Recent laboratory installations and public policy implementations will drive further growth in 2018 and will further reduce the percentage of our revenues from the UK as our share of the very substantial global NIPT market continues to grow – a market which is forecast to exceed $1 billion by 2021.

“We were very disappointed by the first instance judgment in the UK in relation to the Illumina NIPT patent claims, for which we are preparing a robust appeal ahead of the next hearing in late January 2018.  The potential scenarios remain complex and we are reviewing how best to achieve a de-risked IP landscape for investors and customers, with appropriate working capital in place to realise the significant global potential for the Group in 2018 and beyond.

“The Group remains focused on product development and international expansion. We have built a very strong network of distributors and customers in the NIPT space from which we expect to see substantial growth as awareness of the benefits of NIPT continues to grow. In addition, we are accelerating efforts to leverage Premaitha’s scientific expertise into other applications of our molecular diagnostics technology and look forward to announcing exciting developments in due course.”

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For more information, please contact:

Premaitha Health PLC
Dr Stephen Little, Chief Executive Officer

Barry Hextall, Chief Financial Officer

Joanne Cross, Head of Marketing

This email address is being protected from spambots. You need JavaScript enabled to view it.

Tel: +44 (0)161 667 1053

Cairn Financial Advisers LLP (NOMAD)
Liam Murray / James Caithie

Tel: +44 (0)20 7213 0880

finnCap (Broker)

Adrian Hargrave / Scott Mathieson (Corporate Finance)

Andrew Burdis / Abigail Wayne (Corporate Broking)

Tel: +44 (0)20 7220 0500

Vigo Communications

Ben Simons / Fiona Henson / Antonia Pollock

This email address is being protected from spambots. You need JavaScript enabled to view it.

Tel: +44 (0)20 7830 9700

 

About Premaitha

Premaitha is an international molecular diagnostics group which uses the latest advances in DNA analysis technology to develop safer, faster and regulatory approved genetic screening tests. The Group’s primary focus is on non-invasive prenatal tests (NIPT) for pregnant women – an emerging, multi-billion dollar global market.

Premaithas IONA® test was launched in 2015 as the first CE-IVD NIPT test in Europe. It enables laboratories and healthcare practitioners to offer a complete CE-marked NIPT system in-house. The IONA® test is performed on a maternal blood sample which contains traces of fetal DNA – and estimates the risk of a fetus being affected with Downs syndrome or other genetic conditions.

Unlike existing prenatal screening methods, due to its high level of accuracy, the IONA® test can significantly reduce the number of women subjected to unnecessary invasive follow up diagnostic procedures, such as amniocentesis, which are costly, resource intensive and carry a risk of miscarriage.

In March 2017, Premaitha acquired Yourgene Bioscience, a specialist next generation sequencing and bioinformatics company based in Taiwan, with its own NIPT screening test that operates on the same Thermo Fisher next-generation sequencing platform as Premaitha’s IONA® test. Yourgene brings significant benefits to the Group through expanded market access in Asia – the world’s fastest growing NIPT market – as well as opportunities for cross-selling and the ability to jointly develop expanded test content both within NIPT and beyond.

Premaitha is headquartered in Manchester, England, with Yourgene offices in Taipei and Singapore. Its shares trade on the AIM market of the London Stock Exchange (AIM: NIPT). For further information, please visit www.premaitha.com. Follow us on twitter @PremaithaHealth.

  • 29 December 2017 - Half Year Results +

    Premaitha Health PLC
    (“Premaitha”, the “Company” or the “Group”)

    Half year results

    Manchester, UK – 29 December 2017: Premaitha Health PLC (AIM: NIPT), a leading molecular diagnostics group with a primary focus on the commercialisation of its non-invasive prenatal testing (“NIPT”) technology, announces half year results for the six months ended 30 September 2017.

    Financial highlights
    •    Revenues increased by 87% to £2.7m (H1 2016/17: £1.5m)
    •    Test volumes doubled to over 22,000 (H1 2016/17:

    Read More
  • 11 December 2017 - Premaitha secures four further laboratories in Europe +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    Premaitha secures four further laboratories in Europe

    Manchester, UK – 11 December 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (NIPT), announces further expansion of its European customer base, with four new laboratories added.

    The laboratories are situated across three EU countries. The Company’s European distributors secured three of the laboratories, with one laboratory having been contracted directly by

    Read More
  • 01 December 2017 - Premaitha CEO Wins Bionow Outstanding Contribution Award +

    Premaitha CEO Wins Bionow Outstanding Contribution Award

    Steve Little

    Manchester, UK – 1 December 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (NIPT), is proud to announce that its CEO, Dr Stephen Little, last night received Bionow’s Outstanding Contribution award in recognition of his “significant contribution to the biomedical sector.”

    Bionow is an organisation which supports business growth, competitiveness and innovation within the biomedical and life science sectors

    Read More
  • 27 November 2017 - Middle East laboratory network expansion +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    Middle East laboratory network expansion

    Manchester, UK – 27 November 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (NIPT), announces further expansion of its Middle Eastern customer base, with four new laboratories having been signed up in the region.

    Premaitha’s Middle Eastern distributors have secured four new laboratories seeking to offer the IONA ® test to their respective population

    Read More
  • 23 November 2017 - Premaitha signs new partner to offer NIPT solution in East Asia +

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Premaitha signs new partner to offer NIPT solution in East Asia

    Manchester, UK – 23 November 2017: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”), announces that it has signed an agreement with a new laboratory partner (the “Partner”) to offer an NIPT screening solution in a new East Asian territory (the “Territory”) for Premaitha.  

    The Partner is

    Read More
  • 21 November 2017 - Litigation First Instance Judgment +

    Premaitha Health plc
    (“Premaitha” or the “Company” or the “Group”)

    Litigation First Instance Judgment

    Manchester, UK – 21 November 2017: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”), announces details of a legal judgment handed down today.

    The UK High Court has today delivered its first instance judgment (the Judgment) in relation to the ongoing dispute with Illumina Inc and others concerning three UK patent families,

    Read More
  • 13 October 2017 - Commercial progress in the Middle East +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    Commercial progress in the Middle East

    Manchester, UK – 13 October 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (NIPT), announces further commercial progress in the Middle East, where several new contracts have been signed via the Company’s regional distribution network.

    Premaitha has secured contracts with three additional laboratories in the region including in the UAE and Saudi Arabia,

    Read More
  • 29 September 2017 - Full year results to 31 March 2017 and half-year trading update +

    Issued on behalf of Premaitha Health plc
    Manchester, UK: Friday, 29 Sept 2017

    Premaitha Health PLC
    (“Premaitha,” the “Company” or the “Group”)

    Full year results to 31 March 2017 and half-year trading update

    Manchester, UK – 29 September 2017: Premaitha (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”), announces its full year results for the twelve months ended 31 March 2017; and provides an update on trading performance in

    Read More
  • 19 September 2017 - Premaitha to offer NIPT in South Africa +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    Premaitha to offer NIPT in South Africa

    Manchester, UK – 19 September 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing, announces that it has signed an agreement with Ampath group, practising as Drs Du Buisson, Kramer, Swart, Bouwer Inc. (“Ampath”) to offer the Company’s IONA ® test in South Africa, where the Company has appointed Barker Medical Pty Ltd

    Read More
  • 7 September 2017 - Further patent infringement claims received from Illumina & Sequenom +

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Further patent infringement claims received from Illumina & Sequenom

    Manchester, UK – 7 September 2017: Premaitha Health plc (AIM: NIPT) announces that it has today received notification from Illumina and Sequenom that a further claim for patent infringement has been filed in the High Court of Justice in London.

    Premaitha is a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”) and has been robustly defending

    Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
Pregnant lady sitting at table with Laptop

Investor Relations
Ben Simons / Fiona Henson
Vigo Communications
180 Piccadilly
London W1J 9HF
premaitha@vigocomms.com
T : +44 (0) 20 7830 9700

Two business people looking at computer screen